CORT stock news
This page provides real-time market news, earnings updates, and company announcements related to Corcept Therapeutics Incorporated (CORT).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-13 14:19 EST
Pharmaceuticals Stocks Q4 Summary: Ocular Therapeutix (NASDAQ:OCUL)
101 finance2026-03-12 22:39:45
Branded Pharmaceuticals Stocks Q4 Overview: Comparing Zoetis (NYSE:ZTS)
101 finance2026-03-18 21:57:42
CORT Faces Ongoing Legal Uncertainty and July 2026 FDA Decision — Which Event Will Drive Its Valuation Shift?
101 finance2026-03-18 22:00:53
Corcept faces increased scrutiny on its regulatory process as the April 21 legal deadline approaches, with the lawsuit claiming the company hid FDA warnings.
101 finance2026-03-20 08:06:53
Corcept's Insiders Are Selling Millions—Is the FDA Warning Just the Beginning?
101 finance2026-03-20 09:06:47
CORT’s FDA PDUFA Date on July 11: Approval Decision Creates a High-Stakes, High-Potential Trading Opportunity
101 finance2026-03-20 09:07:00
Corcept's July 11 PDUFA Could Overshadow April Lawsuit Deadline as Ovarian Cancer Data Revives Pipeline
101 finance2026-03-21 05:37:16
Corcept’s FDA Gamble: Insider Invests Heavily, Institutional Investors Remain Cautious
101 finance2026-03-21 09:33:45
Companies Now Face the Battlefield Directly. It's Time They Respond Accordingly
101 finance2026-03-21 12:30:54
Corcept Insiders Divided Over Shares: Director Invests $3.3M While CEO Receives Options and Outlook Stays Bearish
101 finance2026-03-23 21:15:38
Corcept Therapeutics Soars: A Remarkable 42% Jump Breaks Expectations
101 finance2026-03-25 15:28:03
Biopharmaceutical company Corcept Medical (NASDAQ: CORT) recently disclosed that the wholesale acquisition cost for a standard 28-day course of its novel endocrine therapy Lobivorli is $37,900.
老虎证券2026-03-25 19:06:45
CORT Shares Surge After FDA Approval of Lifyorli for Platinum-Resistant Ovarian Cancer
101 finance2026-03-26 17:00:47
Smart Money Buys CORT Despite Broken Technicals
101 finance2026-03-27 03:12:41
Corcept’s Low-Volume Breakout Indicates Potential Overbought Trap with Sellers Waiting
101 finance2026-03-27 23:51:54
Corcept's FDA Rejection May Signal a Tactical Buy: Is the Data Gap Overpriced?
101 finance2026-03-28 02:51:38
Corcept’s MOMENTUM Results Confirm Previously Unidentified Patient Group—Upcoming July FDA Ruling Becomes Key Trigger
101 finance2026-03-28 19:12:40
Corcept's April 21 Legal Deadline: A Short-Term Catalyst Amid Patent Loss and Information Gap Risk
101 finance2026-03-30 20:15:52
Cort (CORT) Faces Sell-Off Risk as Optimism Is Priced In, But Earnings Misses Suggest a Guidance Reset Is Coming
101 finance2026-04-03 18:54:46
CORT Insiders Distribute Shares for Free—No Sales—Amid Growing Legal and FDA Challenges
101 finance2026-04-04 01:54:41
CORT’s FDA clearance for ovarian cancer alleviates a significant concern—investors remain cautious about fundamental business challenges
101 finance2026-04-05 02:06:48
Corcept CEO Offloads $1.3M After FDA Nod While Savvy Investors Raise Concerns Over Legal Uncertainty
101 finance2026-04-06 16:40:11
Esperion Therapeutics (ESPR) Drops 10% Following Last Earnings Release: Is a Recovery Possible?
101 finance2026-04-09 16:40:04
Corcept's Relacorilant Binary Hangs Over Stock—Lawsuit Is Secondary Friction, Not Fundamental Risk
101 finance2026-04-13 04:48:40
Corcept's Insiders Are Selling Millions—Is the FDA Warning Just the Beginning?
101 finance2026-03-20 09:06:47
CORT’s FDA PDUFA Date on July 11: Approval Decision Creates a High-Stakes, High-Potential Trading Opportunity
101 finance2026-03-20 09:07:00
Corcept's July 11 PDUFA Could Overshadow April Lawsuit Deadline as Ovarian Cancer Data Revives Pipeline
101 finance2026-03-21 05:37:16
Corcept’s FDA Gamble: Insider Invests Heavily, Institutional Investors Remain Cautious
101 finance2026-03-21 09:33:45
Companies Now Face the Battlefield Directly. It's Time They Respond Accordingly
101 finance2026-03-21 12:30:54
Corcept Insiders Divided Over Shares: Director Invests $3.3M While CEO Receives Options and Outlook Stays Bearish
101 finance2026-03-23 21:15:38
Corcept Therapeutics Soars: A Remarkable 42% Jump Breaks Expectations
101 finance2026-03-25 15:28:03
Biopharmaceutical company Corcept Medical (NASDAQ: CORT) recently disclosed that the wholesale acquisition cost for a standard 28-day course of its novel endocrine therapy Lobivorli is $37,900.
老虎证券2026-03-25 19:06:45
CORT Shares Surge After FDA Approval of Lifyorli for Platinum-Resistant Ovarian Cancer
101 finance2026-03-26 17:00:47
Smart Money Buys CORT Despite Broken Technicals
101 finance2026-03-27 03:12:41
Corcept’s Low-Volume Breakout Indicates Potential Overbought Trap with Sellers Waiting
101 finance2026-03-27 23:51:54
Corcept's FDA Rejection May Signal a Tactical Buy: Is the Data Gap Overpriced?
101 finance2026-03-28 02:51:38
Corcept’s MOMENTUM Results Confirm Previously Unidentified Patient Group—Upcoming July FDA Ruling Becomes Key Trigger
101 finance2026-03-28 19:12:40
Corcept's April 21 Legal Deadline: A Short-Term Catalyst Amid Patent Loss and Information Gap Risk
101 finance2026-03-30 20:15:52
Cort (CORT) Faces Sell-Off Risk as Optimism Is Priced In, But Earnings Misses Suggest a Guidance Reset Is Coming
101 finance2026-04-03 18:54:46
CORT Insiders Distribute Shares for Free—No Sales—Amid Growing Legal and FDA Challenges
101 finance2026-04-04 01:54:41
CORT’s FDA clearance for ovarian cancer alleviates a significant concern—investors remain cautious about fundamental business challenges
101 finance2026-04-05 02:06:48
Corcept CEO Offloads $1.3M After FDA Nod While Savvy Investors Raise Concerns Over Legal Uncertainty
101 finance2026-04-06 16:40:11
Esperion Therapeutics (ESPR) Drops 10% Following Last Earnings Release: Is a Recovery Possible?
101 finance2026-04-09 16:40:04
Corcept's Relacorilant Binary Hangs Over Stock—Lawsuit Is Secondary Friction, Not Fundamental Risk
101 finance2026-04-13 04:48:40
CORT stock chart
CORT stock detailsCORT stock price change
On the last trading day, CORT stock closed at 41.91 USD, with a price change of -0.80% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more